Bli medlem
Bli medlem

Du är här


Promore Pharma: Redeye: Promore Pharma - Uncertainty around PXL01 Phase III development in the U.S.

Promore Pharma announced on January 2nd that Cellastra, their intended
partner for the Phase III development of PXL01 in North America, did
not meet their fundraising goal and hence did not opt in on the

Read more and download the Research Update, with a new fair value

Start following companies at Redeye to receive the latest equity
research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment


Författare Cision

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.